Overcoming resistance to mTOR inhibition for enhanced strategies in clinical trials

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.22, Iss.6, 2013-09, pp. : 679-685

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy

By O'Regan Ruth Hawk Natalyn Nicole

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 7, 2011-07 ,pp. : 859-872

Informa Healthcare

Access to resources Recommend Favorite

A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials

By Wong Michael

Expert Review of Neurotherapeutics, Vol. 13, Iss. 6, 2013-06 ,pp. : 657-669

Informa Healthcare

Access to resources Recommend Favorite

The Applicability of mTOR Inhibition in Solid Tumors

Current Cancer Drug Targets, Vol. 9, Iss. 3, 2009-05 ,pp. : 439-450

Bentham Science Publishers

Access to resources Recommend Favorite

mTOR Inhibition in Lymphoma: A Rational and Promising Strategy

Letters in Drug Design & Discovery, Vol. 4, Iss. 3, 2007-04 ,pp. : 224-231

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic Rationale for mTOR Inhibition in Advanced Renal Cell Carcinoma

Current Clinical Pharmacology, Vol. 6, Iss. 3, 2011-08 ,pp. : 214-221

Bentham Science Publishers

Access to resources Recommend Favorite